Supernus Pharmaceuticals (SUPN) Research & Development (2016 - 2025)
Historic Research & Development for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $29.4 million.
- Supernus Pharmaceuticals' Research & Development rose 113.65% to $29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.1 million, marking a year-over-year increase of 343.88%. This contributed to the annual value of $108.8 million for FY2024, which is 1878.2% up from last year.
- Latest data reveals that Supernus Pharmaceuticals reported Research & Development of $29.4 million as of Q3 2025, which was up 113.65% from $22.1 million recorded in Q2 2025.
- Over the past 5 years, Supernus Pharmaceuticals' Research & Development peaked at $34.3 million during Q1 2021, and registered a low of $15.5 million during Q2 2021.
- In the last 5 years, Supernus Pharmaceuticals' Research & Development had a median value of $22.7 million in 2023 and averaged $23.4 million.
- In the last 5 years, Supernus Pharmaceuticals' Research & Development surged by 8102.13% in 2021 and then plummeted by 3920.95% in 2022.
- Supernus Pharmaceuticals' Research & Development (Quarter) stood at $21.1 million in 2021, then dropped by 15.68% to $17.8 million in 2022, then skyrocketed by 31.35% to $23.3 million in 2023, then rose by 22.7% to $28.6 million in 2024, then increased by 2.51% to $29.4 million in 2025.
- Its Research & Development was $29.4 million in Q3 2025, compared to $22.1 million in Q2 2025 and $26.9 million in Q1 2025.